Compare Teladoc Health Inc (TDOC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teladoc Health Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Teladoc Health Inc trades at $6.09 (market cap $1.14B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals.
| TDOC | XBI | |
|---|---|---|
Market Cap | $1.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $9.72 | $169.55 |
52-Week Low | $4.47 | $93.43 |
Enterprise Value | $1.40B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TDOC trades at $6.26, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $200.32 million in 2025, though revenue remains stable at $2.53 billion. Analyst consensus is a hold with a $8.88 price target, while recent news highlights leadership changes and ongoing legal investigations.
The outlook is cautious; while valuation ratios like P/S of 0.45 and EV/EBITDA of 6.5 appear attractive, persistent losses and negative ROE of -12.99% pose risks. Upside depends on profitability improvements under new CFO Michael Grasher, but investor sentiment is tempered by weak earnings and competitive pressures.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
